MISSISSAUGA, ON, Dec. 20 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has completed accrual in the first 50-patient cohort of its Phase II trial of nimotuzumab in combination with irinotecan for the treatment of colorectal cancer. The safety profile in the trial to date is consistent with data from previous trials of nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), in that there has been no evidence of the severe side effects frequently seen with currently approved EGFR-targeting antibodies and small molecules.
"We are pleased by the enthusiasm of the investigators that resulted in rapid enrollment of this patient cohort and look forward to results from this trial which could provide the evidence to advance nimotuzumab's further development in one of the largest cancer patient populations," said David Allan, Chairman and CEO of YM BioSciences. "Preliminary data on disease control rates should be available toward the end of the first calendar quarter of 2008. Since progression-free survival (PFS) in this patient population historically approximates four months initial observations of nimotuzumab's effect on PFS could be available shortly after the response data."
The single-arm trial in Canada is currently designed to enroll 100
patients in two 50-patient cohorts, consecutively, with the first cohort
receiving irinotecan and weekly dosing of nimotuzumab and the second cohort
receiving irinotecan with nimotuzumab every two weeks. The endpoints of the
trial include the rate and duration of disease control (Stabl
|SOURCE YM BioSciences Inc.|
Copyright©2007 PR Newswire.
All rights reserved